➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Baxter
McKinsey
Merck

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,205,091

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,205,091
Title:Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
Abstract: Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N.sub.2O.sub.2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation. ##STR00001##
Inventor(s): Maciag; Anna E. (Frederick, MD), Keefer; Larry K. (Bethesda, MD), Saavedra; Joseph E. (Thurmont, MD), Anderson; Lucy M. (Catonsville, MD), Chakrapani; Harinath (Pashan Pune, IN)
Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC)
Application Number:13/509,431
Patent Claims:see list of patent claims

Details for Patent 9,205,091

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC) 2029-11-13 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC) 2029-11-13 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC) 2029-11-13 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC) 2029-11-13 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial The United States of America, as represented by the Secretary Department of Health and Human Services (Washington, DC) 2029-11-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Harvard Business School
Johnson and Johnson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.